Goldman Sachs Maintains Neutral on Sage Therapeutics, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Sage Therapeutics and lowers the price target from $75 to $22.
August 09, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has lowered its price target for Sage Therapeutics from $75 to $22 while maintaining a Neutral rating.
The significant reduction in the price target by Goldman Sachs, a major financial institution, could negatively impact investor sentiment towards Sage Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100